hsTropI: an early biomarker of acute coronary syndrome & MI

Neogi S.S.¹, Kapoor R.K.²

¹ Dr Sohini Sengupta Neogi, ² Dr Raj Kumar Kapoor; both authors are affiliated with Department of Biochemistry, BLK Superspeciality Hospital, Pusa Road, Rajinder Nagar, New Delhi, India.

Address for Correspondence: Dr Sohini Sengupta Neogi, E-mail: drsohini9@gmail.com

Abstract

In the Emergency Department cardiac troponins are the preferred biomarkers for the diagnosis of acute myocardial infarction (MI) and are useful for risk stratification of patients with acute coronary syndrome (ACS) and stable ischemic heart disease. The introduction of ‘high sensitivity’ Troponins (hsTn) in many tertiary care centers has transformed the diagnostic scenario, wherein, the time from onset of chest pain to its diagnosis has significantly been reduced. With the advent of new hsTnI assays, which have a low limit of detection, low imprecision and low reference limits, the possibility of more patients with unstable angina being classified as having non-ST-elevation myocardial infarction (NSTEMI) will now increase. Its use will identify more high-risk patients with undifferentiated chest pain, that will help ‘rule-in’ or ‘rule-out’ acute myocardial infarction. In conclusion, it may be said that hsTropI is a sensitive, albeit less specific marker of MI. In patients of mildly elevated hsTropI and without evidence of ST elevation, a serial assessment of the biomarker is suggested. This will likely translate into more improved outcomes in this difficult patient population when ECG findings and clinical presentation do not suggest a clear diagnosis.

Keywords: hs TroponinI (hsTropI), acute coronary syndrome, Non ST elevation MI

Introduction

Cardiovascular disease is the leading cause of death worldwide and coronary artery disease is its most prevalent manifestation. In clinical practice cardiac troponins (cTn) are the cornerstone of diagnosis, risk stratification and selection of optimal treatment strategy in patients with acute coronary syndrome. According to the third update of the universal definition of myocardial infarction (MI), cTn is the preferred cardiac biomarker of myocardial necrosis in the setting of acute myocardial ischemia.

Cardiac troponins I (cTnI) and T (cTnT) have for long, been used as standard biomarkers for detection of myocardial injury, for risk stratification in patients suspected of acute coronary syndrome, and for the diagnosis of myocardial infarction. However, there is increasing evidence based on recent clinical database, which favours the use of high-sensitivity (hs) troponin assays as the initial marker for acute cardiac conditions (1,2).

The purpose of this review is to analyse the significance of the prefix ‘hs’ in the background of the biochemistry of cTn and to address the issues arising from biological variation, assay imprecision characteristics and possible ‘rule-in’ and ‘rule-out’ of myocardial infarction using hs troponin I assays.

Human cTnI occurs in cardiac muscle tissue as a single isoform of 209 amino acid residues, with a molecular weight of approximately 23–24 kDa. Three human cTnI isoforms have been described: one is produced in cardiac muscle (cTnI), and one isoform each is produced in slow-twitch and fast-twitch skeletal muscles (slow sTnI and fast sTnI, respectively) (3).
Significance of ‘hs’: The term “high sensitivity” reflects the characteristics of the assay and does not refer to a difference in the form of cardiac troponin being measured. Several names have been used in the literature for these assays, including “high-performance,” “highly sensitive,” “high-sensitive,” “ultrasensitive,” “novel highly sensitive,” “sensitive,” and “high sensitivity.” In a scorecard concept, an assay is proposed to be ‘high sensitivity’ or ‘hs’ if it meets 2 basic criteria (4). First, the total imprecision (CV) at the 99th percentile value should be $\leq 10\%$. Second, measurable concentrations below the 99th percentile should be attainable with the assay at a concentration value above the assay's limit of detection for at least 50% (and ideally >95%) of healthy individuals to attain the highest level of scorecard designation. Troponin assays have been developed with successive generations such that they can detect increasingly low levels of troponin (5).

This has incrementally reduced the diagnostic cut-offs for the rule-out of MI from 0.5 $\mu$g/L in the first generation assays to the levels of 0.05-0.1 $\mu$g/L (3rd generation), which are in widespread use today. However, the recent development of high-sensitivity troponin (hsTn) assays, which are in use in a few centres, can detect levels as low as 0.003 $\mu$g/L (3 ng/L).The highly sensitive troponin assays remove the need to wait for several hours after the onset of chest pain symptoms required by previous assays in order to reliably detect enough circulating troponin to confirm or exclude MI. It also means that the concept of a 'negative' troponin becomes relatively redundant as troponin at some level can almost always be detected even in healthy patients. These concepts will therefore, have widespread clinical implications. The diagnostic sensitivity of hsTn assays (ability to rule-out MI) are of the order of 90–95% when tested at the point of admission (6,7). When compared with older assays this is a marked improvement, but it still allows the potential for missing 5–10% of all MIs, with potentially adverse consequences for patient care.

The counterpoint to the excellent sensitivity of hsTn testing is a lower specificity (ability to rule-in MI). Although cardiac troponin is, by definition, completely specific for myocardial injury, it is not specific for the diagnosis of acute MI. This leads to a problem for hsTn where specificity has been reported to be 80–85% (6). Phosphorylation of cardiac troponin I (cTnI) by protein kinase C (PKC) is implicated in cardiac dysfunction. Recently, Serine 199 (Ser199) was identified as a target for PKC phosphorylation and increased Ser199 phosphorylation occurs in end-stage failing human myocardium compared to the non-failing myocardium. Ser199 pseudo-phosphorylation decreased cTnI binding to both actin and actin-tropomyosin.

Moreover, altered susceptibility of cTnI to proteolysis by calpain I was found when Ser199 was pseudo-phosphorylated. Published data demonstrate that low levels of cTnI-Ser199 pseudo-phosphorylation (~6%) increase myofilament Ca (2+)-sensitivity in human cardiomyocytes, most likely by decreasing the binding affinity of cTnI for actin-tropomyosin. In addition, cTnI-Ser199 pseudo-phosphorylation or mutation regulates calpain I mediated proteolysis of cTnI (8).
Gender specificity of hs TropI: Gender is an important determinant of cardiovascular risk, and men generally develop cardiovascular disease earlier than women. Increased levels of hs-TnI have been shown to be predictive of cardiovascular death, with stronger effects in women. However, it remains unclear whether the stronger association between hs-TnI and cardiovascular death in women is based on the ability of hs-TnI to predict myocardial infarction (MI) or heart failure (HF). One study aimed at assessing the influence of gender on the association between levels of hs-TnI and incidence of MI and HF. hs-TnI was measured in 5,060 women and 4,054 men (all free from known cardiac disease at baseline) participating in the prospective observational study. The C-index for hs-TnI was stronger for women than men for MI (p <0.001), and it was concluded that in the general population, the association between hs-TnI concentrations and MI is stronger in women than in men. For HF, the impact of gender on the prognostic value of hs-TnI was found to be less pronounced. Increased levels of troponin I in women may thus reflect an adverse phenotype more prone to the development of cardiovascular disease (9).

Another study showed sex-dependent differences in hsTnI in the 99th percentile of healthy population, with concentrations in women being approximately 50% lower. Although increasing the proportion of women with increased troponin I, adopting sex-specific cutoffs with the hs-TnI assay did not lead to an increase in AMI diagnoses in females, or in the number of women undergoing angiography (10). Another study included 2077 adults from the general population aged 25-41 years without cardiovascular disease. cTnI was measured using a high-sensitivity assay. A stepwise backward linear regression analyses was performed to identify variables independently associated with hs-TnI levels. Sex, age, and systolic blood pressure were found to be the strongest determinants of hs-TnI in healthy adults. The 99th percentile was three times higher in men compared to women. Hence, it was concluded that sex-specific cut-off values may be preferable when applying hs-TnI for screening purposes (11).

‘Rule in’ and ‘Rule out’ of AMI: In a prospective, observational study of consecutive patients presenting to emergency departments where high-sensitivity cardiac troponin I (hs-TnI) was measured on clinical indication, the negative predictive value (NPV) and diagnostic sensitivity of an hs-TnI concentration <limit of detection (LoD) at presentation was determined for acute myocardial injury and for AMI or cardiac death at 30 days. It was observed that a single hs-TnI concentration <LoD rules out acute myocardial injury, regardless of etiology, with an excellent NPV and diagnostic sensitivity, and identifies patients at minimal risk of AMI or cardiac death at 30 days (12). Another study compared the incidence of undetectable (below the limit of detection (LoD)), measurable (LoD to 99th percentile), and increased cTnI (concentrations above the 99th percentile) between high-sensitivity cTnI (hs-TnI) and contemporary cTnI assays. It was concluded that the hs-TnI assay provides clinicians with more numeric cTnI concentrations. This occurs via a shift from results below the LoD to those between the LoD and the 99th percentile and does not increase the number of cTnI concentrations above the 99th percentile (13). Early diagnosis of acute myocardial infarction (AMI) can ensure quick and effective treatment but only 20% of adults with emergency admissions for chest pain have an AMI. hs-cTn assays may allow rapid rule-out of AMI and avoidance of unnecessary hospital admissions and anxiety. Eighteen studies were included in a clinical effectiveness review.

The optimum strategy used a limit of blank (LoB) or limit of detection (LoD) threshold (depending on the manufacturers guidelines) in a presentation sample to rule out AMI. Patients testing positive were then subjected to a further test at 2 hours with a conclusion that a result above the 99th centile on either sample and a delta (Δ) of ≥ 20% has some potential for ruling in an AMI whereas a result below the 99th centile on both samples and a Δ of < 20% can be used to rule out an AMI. There was some evidence to suggest that hs-cTnI testing may provide cost-effective approach to early rule-out of AMI. However, further research is needed to clarify optimal diagnostic thresholds and testing strategies (14). The early triage of patients toward rule-out and rule-in of acute myocardial infarction (AMI) is challenging. Therefore, one study aimed at developing a 2-h algorithm high-sensitivity cardiac troponin I (hs-TnI). hs-TnI was measured at presentation and after 2 h in a blinded fashion. A simple algorithm incorporating hs-TnI baseline values and absolute 2-h changes allowed a triage toward safe rule-out or accurate rule-in of AMI in the majority of patients (15). International guidelines recommend that early serial sampling of high sensitivity troponin be used to accurately identify AMI in patients presenting with chest pain. The background evidence for this approach is limited. One study evaluated whether on presentation and 4-hour hs-TnI could be used to accurately rule-out AMI. This study concluded that hs-TnI≥99th percentile thresholds measured on presentation and at 4-hours was not a safe strategy to rule-out AMI in this clinical
Assessment of patients with suspected non-ST elevation myocardial infarction (NSTEMI) is based on cardiac troponin (cTn) levels with the 99th percentile as cut-off. However, cardiovascular risk starts already at lower troponin concentrations. The utility of 2-hour algorithms using the hs-TnI 97.5th percentile as cut-off was estimated. It concluded that the hs-TnI at 97.5th percentile integrated into 2-hour algorithms provided high diagnostic estimates and could, due to better prognostic properties serve as an alternative to the 99th percentile (20). A prospective, multicentric study was conducted to analyse whether levels of hs-cTn below their respective 99th percentile can be used as a single parameter to rule out AMI at presentation. hs-cTn was measured using four different methods (hs-cTnT Roche, hs-TnI Siemens, hs-TnI Beckman Coulter and hs-TnI Abbott) in consecutive patients presenting to the emergency department with acute chest pain and the patients were followed for death or AMI during a mean period of 24 months. It was concluded that normal hs-TnI levels at presentation should not be used as a single parameter to rule out AMI as 6%-23% of adjudicated AMI cases had normal levels of hs-cTn levels at presentation. It also highlighted the lack of standardisation among hs-TnI assays resulting in substantial differences in sensitivity and NPV at the 99th percentile (21). In another study, a third-generation high sensitivity “guidelines acceptable” troponin I assay (hs-TnI) was evaluated against a contemporary “clinically usable” troponin assay (cTnI). Baseline and 90-minute samples of patients suspected to be suffering from acute coronary syndrome were analyzed for cTnI and hs-TnI. Sensitivity, specificity, positive and negative predictive values for AMI and 30-day adverse cardiac events (ACE) were compared. The hs-TnI assay achieved a 90-minute rule out for AMI and detected more than three times as many AMI cases. The specificity increased with the Δ30% criteria. The hs-TnI assay also detected more cases of patient at risk for adverse cardiac events at 30 days (22). Several assays for the measurement of cardiac troponin (cTn) are available, but differences in their analytical performances may affect the diagnosis of acute MI. A survey was conducted at all Danish departments of clinical biochemistry at hospitals receiving patients with suspected acute MI to gather information about the assay and cut-off value used. It was concluded that several assays for the measurement of cardiac troponin (cTn) are available, but differences in their analytical performances may affect the diagnosis of MI (23).

Factors influencing levels of hsTropI: In another study conducted to ascertain correlates of hs-TnI and its incremental prognostic utility for incident coronary heart disease (CHD) among older asymptomatic subjects, hs-TnI was measured in stored baseline serum samples. After a median follow-up of 11.3 years, 164 CHD events were documented. The most significant correlates of hs-TnI were black race, body mass index, hypertension, LDL cholesterol and estimated glomerular filtration rate (eGFR) (24). In another study, blood was collected from apparently healthy individuals and the outcome as to all-cause death and incidence of cardiovascular disease (CVD) and coronary heart disease (CHD) was followed up to 10 years. It suggested that hs-TnI reflects the status of the myocardium even in seemingly healthy individuals and that the measurements of hs-TnI may be useful for primary prediction of heart disease. This could form the basis of future prospective clinical trials for determining whether measuring hs-TnI can be used in the prevention of CVD/CHD (25). Another study compared the diagnostic accuracy of conventional troponin/traditional coronary artery disease (CAD) assessment and hsTnI/advanced CAD assessment for acute coronary syndrome (ACS) during the index...
hospitalization. It was concluded that hsTnI at the time of presentation followed by early advanced coronary CTA assessment improves the risk stratification and diagnostic accuracy for ACS as compared to conventional coronary CTA assessment (26). In another study, the relationship of cardiac troponin (cTn) levels with conventional and ambulatory blood pressure (BP) in young and healthy adults was evaluated. Using a hs assay, hs-TnI was detectable in virtually all participants of a young and healthy population. hs-TnI was independently associated with systolic BP and left ventricular hypertrophy (27). Another study was conducted to determine whether hs-TnI, which is detectable in a higher proportion of normal subjects than hsTnT, is associated with a major adverse cardiovascular event (MACE) in patients of type 2 diabetes mellitus. It demonstrated that elevated hs-TnI in patients with T2DM is associated with increased MACE, HF, MI and cardiovascular mortality. Importantly, a normal hs-TnI level has an excellent negative predictive value for future adverse cardiovascular events during long-term follow-up (28). Another study was designed to evaluate simultaneously conventional cTn together with their corresponding highly sensitive determinations in stable hemodialysis (HD) patients. Ability of cTn to stratify HD patient risk was assessed. A large proportion of patients free of acute coronary syndrome (ACS) were found to have hs-cTnI higher than the 99th percentile which could be seen as a limiting factor for ACS screening (29).

Patients with end-stage renal failure were found to exhibit a chronic elevation of serum cardiac troponin (cTn) concentration. In order to facilitate the diagnosis of myocardial infarction in these patients, it is necessary to distinguish an increased cTn concentration due to a acute event, from that being a manifestation of chronic elevation. It was seen that long-term biological variation of cTn in stable haemodialysis patients is similar to that in healthy individuals and in patients with stable coronary arterial disease. Serial measurements are required to detect significant changes in cTn concentrations and support diagnosis of myocardial infarction in these patients (30). A well-characterized community-based cohort of 2042 study participants underwent clinical assessment and echocardiographic evaluation. Baseline hs-TnI measurements were obtained in 1843 individuals. Measurable hs-TnI was identified in 93% of the community-based study cohort and 88% of the healthy reference cohort.

Parameters that significantly contributed to higher hs-TnI concentrations in the healthy reference cohort included age, male sex, systolic blood pressure, and left ventricular mass. Glomerular filtration rate and body mass index were not independently associated with hs-TnI in the healthy reference cohort. Individuals with diastolic and systolic dysfunction, hypertension, and coronary artery disease (but not impaired renal function) had significantly higher hs-TnI values than the healthy reference cohort (31).

Conclusion

It has been seen generally that chest pain is a common presenting symptom in the emergency department; however, the majority of these chest pain admissions are not due to AMI. AMI can be life threatening and early diagnosis or rule out of AMI might potentially improve morbidity and mortality, as well as reduce time to decision and overall treatment costs. Over the last few years newer hs-cTn assays have been developed that are more sensitive than conventional assays, have low limit of detection, low imprecision and low reference limits.

The development of hsTropI assays enables precise quantification of extremely low troponin concentrations. Such hs-tropI assays are recommended in early rule-out protocols for AMI, when measured at presentation and again at 3-6 h. With the advent of new hs-TnI assays, more patients with unstable angina will be classified as having non-ST-elevation myocardial infarction. The use of hs-TnI assays will identify more high-risk patients among millions who present to the Emergency Departments each year with undifferentiated chest pain. This will likely translate into more appropriate care and improved outcomes in this difficult patient population when ECG findings and clinical presentation do not suggest a clear diagnosis. Recent studies have shown that their utilization seems to improve the diagnostic accuracy in detecting MI in patients presenting with chest pain. However, the improved sensitivity comes along with a decreased specificity, though serial hs-TnI measurements and the detection of early changes could improve the specificity and the overall diagnostic performance. Moreover, apart from their use in the diagnosis and risk stratification of MI and acute coronary syndromes, hs-TnI assays seem to have a key role in risk stratification and short and long-term prognosis in a variety of cardiovascular modalities such as stable coronary disease, heart failure...
and acute pulmonary embolism. In addition, studies have suggested that hs-TnI may be used as a biomarker in the primary prevention of cardiovascular disease leading to the identification of high-risk populations or individuals with silent heart disease.

However, due to assay variability, the deployment of a standardization and harmonization method is required before their wide use in clinical practice. In conclusion, it may be said that these hs-TnI assays will define a high-risk patient population that was not possible with older generation assays and will probably lead to more appropriate therapy and improved outcomes in these patients.

Acknowledgement: We thank Dr Anil Handoo, Director, Department of Laboratory Services, BLK Superspeciality Hospital, Delhi for his encouragement and support in writing this review.

Funding: Nil, Conflict of interest: None.

Permission of IRB: Yes

References


International Journal of Medical Research and Review Available online at: www.ijmrr.in


How to cite this article?